Daily AI-curated articles on clinical trials, FDA updates, and pharmaceutical insights.
The FDA announces a public meeting to gather feedback on its Commissioner's National Priority Voucher pilot program, signaling potential changes to drug development incentives.
Rhythm Pharmaceuticals' Imcivree receives FDA approval for acquired hypothalamic obesity, marking first treatment option for this challenging condition.
FDA's new draft guidance on New Approach Methodologies (NAMs) promises to accelerate drug development while reducing animal testing through human-centric validation methods.
Fierce Pharma's annual drug naming tournament highlights critical considerations for clinical researchers in pharmaceutical branding and nomenclature.
The FDA has approved a higher 7.2mg dose of Wegovy (semaglutide) under the Priority Review Voucher Program, expanding treatment options for adult weight management.
FDA approves Icotyde, the first once-daily oral TYK2 inhibitor for psoriasis, potentially disrupting the injectable-dominated market with blockbuster sales projected.
The FDA announces new streamlining measures for biosimilar development, potentially reducing drug development timelines and increasing affordable access to biologic therapies.
Positive Phase 3 results position Eli Lilly's IL-13 inhibitor Ebglyss for potential expansion to younger children with atopic dermatitis, addressing critical unmet needs.
